


Nuvonis provides a GMP Vero cell bank ready for industrial biomanufacturing - the world's leading continuous mammalian substrate, proven to be non-tumorigenic.

Nuvonis Vero cell bank originates from a WHO cell bank established in 1987 at passage level 134.

Cultivated under serum-free and animal component-free conditions, this adherent non-GMO cell line provides a safe, reliable platform globally accepted by authorities.



Vero cells © Nuvonis

Key features

- Fully Characterized GMP Cell Banking System: GMP Master, Working, and End of Production Cell bank with complete ICH/WHO compliant testing
- Animal Component-Free: Cultured in serum-free and animal-component free conditions for safe, reproducible manufacturing
- GMP Manufacturing-Ready: Delivered ready-to-use, enabling a direct start into clinical or commercial GMP manufacturing, reducing your time-to-clinic
- Comprehensive Regulatory Support & Proven Track Record: Backed by regulatory expertise and dossier-ready data for successful submissions
- Global Availability & Support: Supplied from multiple GMP sites in the EU and US, with full regulatory documentation and technical guidance
- Ready for Development: Research Cell bank of the same origin available, comparable in passage level and growth characteristics to Nuvonis GMP Cell bank

Applications

Virus Vaccine Production: Robust platform for various human & veterinary vaccines incl. influenza, polio or rabies
Viral Vector and VLP Manufacturing: Supports immunotherapy and virus-like particles for research and clinical use
Virus Isolation and Diagnostics: Ideal for isolating and screening viruses in diagnostics and antiviral development

Advantages

Reliable Supply: Ensuring consistent availability from development to market

Regulatory Compliant: Fully tested and characterized in accordance with EU, US, WHO, and ICH Q5D guidelines

Flexible Licensing: Tailored licensing options to suit your development and manufacturing needs

Literature references

Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 2009; 5: 607-18

Chupin C, Brun P, Ray M, et al. Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor. NPJ Vaccines. 2025; 10(1): 202

Learn more about our services

Nuvonis Technologies GmbH
Mariahilfer Strasse 101/1/21, AT 1060 Vienna, Austria
office@nuvonis.com

